Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 12, 2014, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $463.50 to $302,316,738.76.

Highlighted Stocks Traded by Insiders:

Impax Laboratories (IPXL) - FREE Research Report

Fleming Nigel, who is Director at Impax Laboratories, sold 1,333 shares at $26.58 on May 12, 2014. Following this transaction, the Director owned 8,366 shares meaning that the stake was reduced by 13.74% with the 1,333-share transaction.

The shares most recently traded at $26.33, down $0.25, or 0.96% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 223,386
  • 12-Week # shares sold: 227,386
  • 24-Week # shares sold: 230,386

The average volume for Impax Laboratories has been 782,300 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 6.13% year-to-date as of the close of trading on Monday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 2652.0. Currently, there are 2 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

InterMune (ITMN) - FREE Research Report

Nolan Sean P., who is Executive VP & CBO at InterMune, sold 2,644 shares at $35.85 on May 12, 2014. Following this transaction, the Executive VP & CBO owned 72,556 shares meaning that the stake was reduced by 3.52% with the 2,644-share transaction.

The shares most recently traded at $35.72, down $0.13, or 0.36% since the insider transaction. Historical insider transactions for InterMune go as follows:

  • 4-Week # shares sold: 3,673
  • 12-Week # shares sold: 146,698
  • 24-Week # shares sold: 286,698

The average volume for InterMune has been 3.6 million shares per day over the past 30 days. InterMune has a market cap of $3.6 billion and is part of the health care sector and drugs industry. Shares are up 145.96% year-to-date as of the close of trading on Monday.

InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. Currently, there are 8 analysts who rate InterMune a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITMN - FREE

TheStreet Quant Ratings rates InterMune as a sell. Among the areas we feel are negative, one of the most important has been generally deteriorating net income. Get the full InterMune Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Keurig Green Mountain (GMCR) - FREE Research Report

Coca Cola Co, who is 10% Owner at Keurig Green Mountain, bought 2.8 million shares at $107.76 on May 12, 2014. Following this transaction, the 10% Owner owned 19.5 million shares meaning that the stake was reduced by 16.82% with the 2.8 million-share transaction.

The shares most recently traded at $121.58, up $13.82, or 11.37% since the insider transaction. Historical insider transactions for Keurig Green Mountain go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 1,258
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 26,258
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 34,213

The average volume for Keurig Green Mountain has been 3.5 million shares per day over the past 30 days. Keurig Green Mountain has a market cap of $17.7 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 46.56% year-to-date as of the close of trading on Monday.

Keurig Green Mountain, Inc. is engaged in the specialty coffee and coffeemaker businesses in the United States and Canada. The company operates through two segments, Domestic and Canada. The stock currently has a dividend yield of 0.92%. The company has a P/E ratio of 30.7. Currently, there are 6 analysts who rate Keurig Green Mountain a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GMCR - FREE

TheStreet Quant Ratings rates Keurig Green Mountain as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Keurig Green Mountain Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null